文章摘要
王玉娟,薛亚妮,陈 伟,高健全,刘文林.痰热清注射液对COPD患者血清TGF-β与MMP-9水平的影响[J].,2017,17(22):4325-4329
痰热清注射液对COPD患者血清TGF-β与MMP-9水平的影响
Effect of Tanreqing Injection on Serum Levels of TGF-β and MMP-9 of Patients with COPD
投稿时间:2017-01-18  修订日期:2017-02-15
DOI:10.13241/j.cnki.pmb.2017.22.030
中文关键词: 慢性阻塞肺疾病  痰热清注射液  转化生长因子-β  基质金属蛋白酶-9
英文关键词: Chronic pulmonary obstruction pulmonary disease  Tanreqing injection  Transforming growth factor-β  Matrix metalloproteinases-9
基金项目:陕西省卫计委基金项目(2016D082)
作者单位
王玉娟 延安大学附属医院 呼吸内科 陕西 延安 716000 
薛亚妮 延安大学附属医院 呼吸内科 陕西 延安 716000 
陈 伟 延安市第二人民医院 结核与呼吸科 陕西 延安 716000 
高健全 延安大学附属医院 呼吸内科 陕西 延安 716000 
刘文林 延安大学附属医院 呼吸内科 陕西 延安 716000 
摘要点击次数: 179
全文下载次数: 66
中文摘要:
      摘要 目的:分析痰热清注射液对慢性阻塞性肺病(COPD)患者血清转化生长因子-β(TGF-β)与基质金属蛋白酶-9(MMP-9)水平的影响。方法:将102例COPD患者按随机数表法分作对照组与观察组,各52例。对照组予以常规治疗,观察组基于对照组加用痰热清注射液治疗,比较两组治疗前后血清TGF-β、MMP-9水平,用力肺活量(FVC)、1s用力呼气容积(FEV1),二氧化碳分压(PaCO2)、氧分压(PaO2),CD4+、CD8+、CD4+/CD8+,证候积分,临床疗效及不良反应的发生情况。结果:治疗后,观察组血清TGF-β、MMP-9水平、PaCO2、证候积分均显著低于对照组,PaO2、CD4+、FVC、FEV1、CD4+/CD+、治疗总有效率均显著高于对照组(P<0.05)。两组药物副反应的发生情况比较差异无统计学意义(P>0.05)。结论:痰热清注射液可有效降低COPD患者血清TGF-β及MMP-9水平,并改善患者动脉血气、肺功能及免疫功能。
英文摘要:
      ABSTRACT Objective: To analyze the effect of tanreqing injection on the serum levels of transforming growth factor-β (TGF-β) and matrix metalloproteinases-9 (MMP-9) of patients with chronic obstructive pulmonary disease (COPD). Methods: 102 patients with COPD were divided into the control group and the observation group according to random number table method, 52 cases in each group. The control group was treated with routine therapy, and the observation group was treated with Tanreqing injection based on the control group. The serum TGF-β, MMP-9 levels, forced vital capacity (FVC), 1s forced expiratory volume (FEV1), partial pressure of carbon dioxide (PaCO2),oxygen partial pressure (PaO2), CD4+, CD8+, CD4+/CD8+, syndrome integral, clinical efficacy and incidence of side effects were observed and compared between the two groups. Results: After treatment, the serum TGF-β, MMP-9 levels, PaCO2 and syndrome integral of observation group were significantly lower than those of the control group, the PaO2, CD4+, FVC, FEV1, CD4+/CD8+ and the clinical efficacy of observation group were obviously higher than those of the control group (P<0.05). There was no significant difference in the incidence of side effects between the two groups (P>0.05). Conclusion: Tanreqing injection could effectively reduce the serum levels of TGF-β and MMP-9, and improve the arterial blood gas, lung function and immune function in treatment of patients with COPD.
查看全文   查看/发表评论  下载PDF阅读器
关闭